<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-copd-case-study-ai-enrollment</loc><video:video><video:publication_date>2026-06-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/b995c54f0f330d98cc51589d16cd8648d5349627-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment ]]></video:title><video:description><![CDATA[In this video interview, Liz Beatty, co-founder and chief strategy officer at Inato, shares results from a Sanofi COPD study where AI-enabled sites screened patients 33% faster and achieved 100% enrollment success—including one site that had been non-performing for over 100 days.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6397332006112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-real-time-patient-data-clinops-efficiency</loc><video:video><video:publication_date>2026-06-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/894b71f62a4acdb95091da9126c96954444fdbcc-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE X: What Real-Time Patient Data Is Doing to ClinOps Efficiency ]]></video:title><video:description><![CDATA[In this video interview, Liz Beatty, co-founder and chief strategy officer at Inato, explains how AI is replacing unreliable feasibility estimates with precise, real-time patient matching—and what that means for reducing non-enrolling sites and screen failure rates.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6397332188112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-industry-ai-architecture-clinical-trials</loc><video:video><video:publication_date>2026-06-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/f3a1fa384ab5442e8b8043130320ba1fc9dc38e7-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE X: What the Industry Needs to Understand About AI Architecture in Clinical Trials ]]></video:title><video:description><![CDATA[In this video interview, Abraham Gutman, founder and CEO of AG Mednet, shares his key takeaways from SCOPE X, including a pointed caution against the idea that agentic AI can run clinical trials autonomously and why process architecture is the real entry point for AI to deliver on its promise.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6396866698112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-infrastructure-human-experts-decisions</loc><video:video><video:publication_date>2026-05-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9913d43165b326a1113818d8124ec6cb5d2d24d9-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE X: How the Right Infrastructure Frees Human Experts to Actually Make Decisions ]]></video:title><video:description><![CDATA[In this video interview, Abraham Gutman, founder and CEO of AG Mednet, describes how AI can take on rote reasoning tasks like PHI redaction and document QA, and why offloading that work is what gives human experts the clarity to focus on genuine decision making.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6396867677112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-clinical-trials-operational-conductor</loc><video:video><video:publication_date>2026-05-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/106e4b499f7594239142918f42a310381df8010e-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE X: Why Clinical Trials Still Need an Operational Conductor ]]></video:title><video:description><![CDATA[In this video interview, Abraham Gutman, founder and CEO of AG Mednet, explains why decades of progress in data capture have not solved the execution problem in clinical trials, and what an operational architecture for AI actually looks like in practice.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6396867102112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/early-phase-trials-consequential</loc><video:video><video:publication_date>2026-05-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/6d1bacef28f2ab1a5b7c64e68d2b30742d7a4aa3-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Getting Early Phase Trials Right Is So Consequential ]]></video:title><video:description><![CDATA[In this video interview, Sam Hinsley, statistics manager at Phastar, explains why early phase decisions are the foundation of the entire development pathway and what is at stake statistically when those decisions are made on limited data.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395963281112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/early-phase-esig-accomplish</loc><video:video><video:publication_date>2026-05-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/0655ede57c16342e308ff6687f3f985391dd6bd1-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Inside the Early Phase ESIG and What It Aims to Accomplish ]]></video:title><video:description><![CDATA[In this video interview, Sam Hinsley, statistics manager at Phastar, introduces the Early Phase ESIG, a new special interest group bringing together statisticians from across academia and industry to share knowledge and raise standards in early phase research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395961934112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/cross-stakeholder-collaboration-essential-clinical-trial-innovation</loc><video:video><video:publication_date>2026-05-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/503404ddfbd28fbd913683a76aa010bd2121d0db-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Cross-Stakeholder Collaboration Is Essential to Clinical Trial Innovation ]]></video:title><video:description><![CDATA[In this video interview, Sam Hinsley, statistics manager at Phastar, makes the case that as trial designs grow more complex, collaboration between statisticians and clinical experts is not just helpful but necessary to get meaningful answers.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395961846112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/statisticians-clinical-development</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9ce1c22a0baa347a85c7f53e9a118c6bf79f084f-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Statisticians Can Help Raise Standards Across Clinical Development ]]></video:title><video:description><![CDATA[In this video interview, Sam Hinsley, statistics manager at Phastar, explains how statisticians can ensure patient data is used responsibly and innovatively across every phase of development, from rare disease to personalized medicine to AI.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395962976112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinical-trials-day-mean-you</loc><video:video><video:publication_date>2026-05-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/4640efe33dbc21770ce908e8067f890a5a149d13-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What Does Clinical Trials Day Mean to You?]]></video:title><video:description><![CDATA[In this video interview, Sam Hinsley, statistics manager at Phastar, reflects on why she chose a career in clinical trials and what it means to do work that she believes makes a genuine difference.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395961935112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/operational-realities-building-representative-clinical-trials</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/a808fe5468333c02b26dd68a3012031801100fd3-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Operational Realities of Building More Representative Clinical Trials ]]></video:title><video:description><![CDATA[In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive and strategist; and Adrelia Allen, executive director of clinical trial patient diversity at Merck, Allen describes how improving representation has changed trial design and site selection at Merck, where the hardest barriers remain, and what the industry will need to sustain meaningful progress over the next five years.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395442903112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/lets-talk-trials-access-trust-gap</loc><video:video><video:publication_date>2026-05-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/b38dcde11e942f524ac3a143830f426cc873fd4d-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What Let's Talk Trials Is Doing to Close the Access and Trust Gap ]]></video:title><video:description><![CDATA[In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive and strategist; and Adrelia Allen, executive director of clinical trial patient diversity at Merck, Allen explains how Let's Talk Trials was designed to address gaps in clinical trial awareness and access, what differentiates it from earlier efforts, and how trust sits at the center of the initiative's approach.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395442690112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/merck-representation-clinical-trial-execution</loc><video:video><video:publication_date>2026-05-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9437237d6fcc6d7eba9780ec25612b7cc38ad55e-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Merck Is Embedding Representation Into Clinical Trial Execution ]]></video:title><video:description><![CDATA[In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive and strategist; and Adrelia Allen, executive director of clinical trial patient diversity at Merck, Allen discusses how diversity in clinical trials has become embedded in how Merck designs and executes its studies, and what accountability looks like internally across trial planning and community engagement.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6395443858112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/community-engagement-long-term-value-enrollment</loc><video:video><video:publication_date>2026-05-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/16b297eec7b157dfc2ab6b67692807ef5ad83a63-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Community Engagement Creates Long-Term Value Beyond Enrollment ]]></video:title><video:description><![CDATA[In this video interview, Del Smith, PhD, CEO and co-founder of Acclinate, explains how deep community relationships generate insights that improve protocol design, endpoint selection, and site placement, while building an on-ramp that compounds in value across future studies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391664716112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/resilient-clinical-supply-chain</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/513601695f165f3b50afb28024492e1e6e0258fc-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What a Truly Resilient Clinical Supply Chain Actually Looks Like ]]></video:title><video:description><![CDATA[In this video interview, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, moves past the buzzwords to describe what supply chain resilience means in practice, and why continuity may now deserve to sit above compliance in a sponsor's order of priorities.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6394092510112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/geopolitical-disruption-clinical-supply-chain-planning</loc><video:video><video:publication_date>2026-05-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/5692472f5c181a93913e5a1b9153983a761ee9f2-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Geopolitical Disruption Is Changing Clinical Supply Chain Planning ]]></video:title><video:description><![CDATA[In this video interview, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, discusses why sponsors must now treat disruption as an expected condition and how real-time visibility and connected systems enable faster, more adaptive responses.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6394093385112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/labeling-errors-propagate-patient-safety</loc><video:video><video:publication_date>2026-05-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/c00a991167b7fd43da0b41355fd88f05fa4e1f75-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Labeling Errors Propagate and What That Means for Patient Safety ]]></video:title><video:description><![CDATA[In this video interview, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, traces how small documentation errors move through a fragmented supply chain and ultimately erode the trust that patients and regulators depend on.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6394092511112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/disconnected-systems-fail-sponsors-cmo</loc><video:video><video:publication_date>2026-04-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/6331face3e9f77d5a24056554627af0fdbb58009-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Where Disconnected Systems Fail Sponsors and CMOs Most ]]></video:title><video:description><![CDATA[In this video interview, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, examines how siloed data and manual handoffs create version drift, visibility gaps, and failures that go undetected until the operational damage is already done.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6394092892112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinical-supply-chain-fragmentation-resilience-problem</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/17a5bc6bf4d5ff883e035f30e247708d5eb86b43-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Clinical Supply Chain Fragmentation Is Now a Resilience Problem ]]></video:title><video:description><![CDATA[In this video interview, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, explains how growing trial complexity has shifted the fundamental supply chain question from efficiency to continuity, and why even small changes can cascade into trial interruptions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6394093777112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/execution-breaks-down-governance-ai</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/ec190e5cc236b51ed170300bb6d1c65e76843d97-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Where Execution Breaks Down When Governance Can't Keep Up with AI ]]></video:title><video:description><![CDATA[In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, identifies governance inertia and review cycle lag as the most underappreciated risks when AI speeds up protocol development faster than organizations can act on the insights it generates.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393574132112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/promise-reality-ai-protocol-development</loc><video:video><video:publication_date>2026-04-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/ec31526842329f95d1946960773e83b3bcacf4bb-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Promise and Reality of AI in Protocol Development ]]></video:title><video:description><![CDATA[In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, offers a measured look at where AI is genuinely accelerating upstream protocol work and why proof points of faster approvals reaching patients are still limited.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393574326112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/reimbursement-trial-design-start</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/c4d618d7e24432192448e5405a7ddb71c5df2783-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Reimbursement Needs to Be Part of Trial Design from the Start ]]></video:title><video:description><![CDATA[In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, makes the case for integrating reimbursement probability into the standard PTRs framework earlier in development, and what happens when sponsors reach approval without a viable value story.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393573020112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/trial-design-obesity-oncology</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/ec7796b43290e1f45a201699428762dd4a08f448-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What Makes Trial Design So Hard in Obesity and Oncology Right Now ]]></video:title><video:description><![CDATA[In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how crowded pipelines, compressed IP timelines, and competitive differentiation pressures are forcing smaller sponsors to treat protocol design as a core element of business strategy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393574133112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/trial-design-leadership-decision</loc><video:video><video:publication_date>2026-04-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/fe3f4ed1cd536f67cabcd406e55fe5c887d6fa38-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Trial Design Has Become a Leadership Decision ]]></video:title><video:description><![CDATA[In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, explains why the most consequential shift in clinical trial design is not methodological but organizational, and what an analysis of 200 FDA complete response letters reveals about where decisions are going wrong.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393573019112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/building-trust-framework-delivers-real-roi-sponsors</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/7b11bc2fbc1fee6154fc8272761b71a44e00648d-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Building a Trust Framework That Delivers Real ROI for Sponsors ]]></video:title><video:description><![CDATA[In this video interview, Del Smith, PhD, CEO and co-founder of Acclinate, outlines what a practical, sustained community engagement framework looks like in practice and how sponsors can translate that investment into faster, more efficient, and more representative enrollment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391664813112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/sponsors-structuring-development-plans-plausible-mechanism-framework</loc><video:video><video:publication_date>2026-04-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/75088349eebf93ff3ce10a42de5d6b94ecd67997-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Sponsors Should Be Structuring Development Plans Around the Plausible Mechanism Framework Right Now ]]></video:title><video:description><![CDATA[In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, outlines the steps sponsors can take today—from early FDA engagement and robust non-clinical programs to adaptive trial designs and confirmatory evidence packages—to avoid delays as the guidance moves toward finalization.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393039826112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/evidentiary-risks-natural-history-data-external-control-comparability</loc><video:video><video:publication_date>2026-04-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/68d38297202d672defbb235d5a2113257a490a2b-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Evidentiary Risks of Natural History Data and How to Approach External Control Comparability ]]></video:title><video:description><![CDATA[In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, discusses how heterogeneity in disease course and patient characteristics creates confounding risk when using natural history data as an external control, and what sponsors need to do to achieve meaningful patient matching.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393039541112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/master-protocols-plausible-mechanism-framework</loc><video:video><video:publication_date>2026-04-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/77fcd57721a14ccb8946aff2fa96a4e73cfc0994-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Where Master Protocols Are Most Vulnerable Under the Plausible Mechanism Framework ]]></video:title><video:description><![CDATA[In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, examines the biological, dosing, and population-level considerations that sponsors must get right from the start when using basket and other master protocol designs to evaluate individualized therapies across multiple conditions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393037872112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/regulators-assess-substantial-evidence-trial-populations-traditional-designs</loc><video:video><video:publication_date>2026-04-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/b759b0db564c87ba4707832024c34686708ad98b-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Regulators Assess Substantial Evidence When Trial Populations Are Too Small for Traditional Designs ]]></video:title><video:description><![CDATA[In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, breaks down how the FDA evaluates substantial evidence of effectiveness for individualized therapies in ultra-rare conditions, and why that determination depends on the totality of mechanistic, biomarker, and clinical outcome data rather than trial numbers alone.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393037090112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/fda-plausible-mechanism-framework-approval-individualized-therapies</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/f89aa9dfadd634b44f9682059ad6c521d8ce50d6-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How FDA's Plausible Mechanism Framework Changes the Path to Approval for Individualized Therapies ]]></video:title><video:description><![CDATA[In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, explains how the plausible mechanism framework reshapes the development timeline for individualized therapies by allowing first-in-human studies to serve as pivotal trials and giving sponsors earlier clarity on the evidence needed for approval.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6393037188112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/veeva-new-approach-scalable-esource-research-sites</loc><video:video><video:publication_date>2026-04-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/ab0699f4c10a8866d900ee7bd21870ad5c50c183-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Veeva Is Taking a New Approach to Scalable eSource for Research Sites]]></video:title><video:description><![CDATA[In this video interview, Nick Frenzer, general manager of site solutions at Veeva Systems, discusses why eSource has been difficult to implement at scale, how FHIR-based technology is changing that, and what Veeva eSource means for sites, sponsors, and the broader clinical trial ecosystem.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392874337112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinical-trials-2026-trends-shaping-year-ahead</loc><video:video><video:publication_date>2026-04-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/6db137bf52149cccadfb3a12dbb96ce926a9badc-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Clinical Trials in 2026: Trends Shaping the Year Ahead]]></video:title><video:description><![CDATA[In this video compilation, industry experts share their perspectives on the operational, technological, and methodological shifts defining clinical research in 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392821909112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/how-agentic-ai-realistically-reshape-clinical-trial-workforce</loc><video:video><video:publication_date>2026-04-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/e6009bea94d2644d4fdf84f8d2c6562f23a2adad-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Agentic AI Will Realistically Reshape the Clinical Trial Workforce ]]></video:title><video:description><![CDATA[In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, introduces a practical augmentation scale for thinking about how AI agents will transform clinical trial roles over the next two years and why workforce planning for that shift needs to start now.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392506715112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/patient-centered-ai-greatest-impact-trial-timelines</loc><video:video><video:publication_date>2026-04-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9b1143725abef627a94292eb261e60f477574dab-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Where Patient-Centered AI Has the Greatest Impact on Trial Timelines ]]></video:title><video:description><![CDATA[In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, maps the highest-impact opportunities for AI across the trial lifecycle—from smarter protocol design and enrollment matching to data collection, cycle time compression, and the emerging potential of synthetic data in rare disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392508532112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/patient-first-digital-strategy-practice</loc><video:video><video:publication_date>2026-04-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/33af2a56b8ac370b8cb1a6a40dac89e8c9064ab9-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What a Truly Patient-First Digital Strategy Looks Like in Practice ]]></video:title><video:description><![CDATA[In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, argues that effective patient-centered AI must go beyond direct-to-patient tools to address social determinants of health and reduce the administrative burden on sites so that investigators can focus predominantly on the patient.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392505727112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/organizational-factors-determine-ai-efficiency-gains</loc><video:video><video:publication_date>2026-04-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/c9e05271d164e54a9a38572c3ccb1cf391f45a6b-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Organizational Factors That Determine Whether AI Delivers Real Efficiency Gains ]]></video:title><video:description><![CDATA[In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, outlines the leadership priorities, team structures, and boundary-spanning capabilities that separate organizations that realize meaningful AI gains from those that struggle to move beyond the pilot stage.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392510709112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/successfully-implement-ai-clinical-case-intake</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/2de6ed0c1008778c92439ae6b7d51828fb11ba2b-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What It Takes to Successfully Implement AI in Clinical Case Intake ]]></video:title><video:description><![CDATA[In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, explains how AI is being applied to case intake today and why successful adoption depends less on technology than on reimagining workflows and investing in workforce upskilling.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392505522112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinops-leaders-evolving-tech-stacks</loc><video:video><video:publication_date>2026-04-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/e0a3b1b171a972c0cdbb0af45bfac06389d3d2d6-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How ClinOps Leaders Should Think About Evolving Their Tech Stacks ]]></video:title><video:description><![CDATA[In this video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, offers a framework for thinking about which emerging trial complexities deserve to be built into core technology platforms and which are better managed as bespoke, one-off configurations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391770869112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/veridix-document-authoring-your-ai-co-author-for-clinical-documents</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/1b0f64542b65f1649c09531a9573fd509bbb0c25-1482x827.png</video:thumbnail_loc><video:title><![CDATA[Veridix Document Authoring: Your AI Co-Author for Clinical Documents]]></video:title><video:description><![CDATA[Nageswara Kollu, Senior Director at Apellis Pharmaceuticals, explains how the discovery team leverages AI to automate preclinical documentation and regulatory filings, improving consistency and achieving significant time savings in the drug development process.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6392272575112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/usability-data-quality-issue-design-preference</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/74b34d0433f8dd1044a046c691cba921eaf29078-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Usability Is a Data Quality Issue, Not Just a Design Preference ]]></video:title><video:description><![CDATA[In this video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, makes the case that intuitive, easy-to-navigate technology directly reduces errors, improves site compliance, and prevents the workarounds that quietly undermine study performance.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391770187112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/digital-physical-supply-chains-continuous-system</loc><video:video><video:publication_date>2026-03-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9b84f39ef9d0c2cd9bf5a0c9e0d218746f757589-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Treating Digital and Physical Supply Chains as One Continuous System ]]></video:title><video:description><![CDATA[In this video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, discusses why sponsors must integrate their digital and physical supply chains as a single operational flow and how to build the in-house capabilities and partner relationships needed to manage that complexity effectively.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391769691112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/workflow-guidance-gap-eclinical-ecosystems</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/17a7a8951e3dfcf24bada0fe8525b166796b0da8-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Workflow Guidance Gap Holding Back eClinical Ecosystems ]]></video:title><video:description><![CDATA[In this video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, examines why current eClinical technology too often prioritizes data flow over the day-to-day needs of users and what a truly guided workflow experience should look like for busy site teams.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391769109112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/effective-clinical-trial-tech-stack</loc><video:video><video:publication_date>2026-03-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/8ff39b036bc06b96a68c3acb163e9b737e84dd77-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What It Really Means to Build an Effective Clinical Trial Tech Stack ]]></video:title><video:description><![CDATA[In this video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, explains why an effective tech stack must be purpose built, fully integrated, and designed above all to simplify the execution of clinical research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391768615112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/barriers-underrepresented-community-participation-clinical-trials</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/87184db1d433f5b325cab92ad47f38e6e262716a-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Breaking Down the Barriers to Underrepresented Community Participation in Clinical Trials ]]></video:title><video:description><![CDATA[In this video interview, Del Smith, PhD, CEO and co-founder of Acclinate, examines the structural and relational barriers that keep underrepresented communities out of clinical trials and explains how authentic, sustained community engagement differs from traditional recruitment outreach.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391664313112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/ai-wearables-transform-clinical-oversight</loc><video:video><video:publication_date>2026-03-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/cf0484b6c96c9b450ba72a855880cdc3af470359-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How AI and Wearables Together Could Transform Clinical Oversight ]]></video:title><video:description><![CDATA[In this video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, explores how AI models capable of analyzing continuous wearable data streams alongside broader patient information could detect subtle warning signs of deterioration that no clinician could identify alone.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391087029112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/fda-clearance-reimbursement-models-wearable-adoption</loc><video:video><video:publication_date>2026-03-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/46cae860ef48b668b5dae4da1b6bd38aa7cd9587-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How FDA Clearance and Reimbursement Models Shape Wearable Adoption ]]></video:title><video:description><![CDATA[In this video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, discusses how regulatory trust-building and reimbursement reform are essential to making wearable devices a sustainable and widely adopted part of clinical care delivery.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391085740112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/thinking-learning-human-factors-optimizing-clinical-operations</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/5a821be8adfa37fe3be2ca62007b3a173b3e8b92-1268x706.png</video:thumbnail_loc><video:title><![CDATA[From Thinking to Learning to Doing: Human Factors Optimizing Clinical Operations]]></video:title><video:description><![CDATA[Brian S. McGowan, PhD, chief learning officer at ArcheMedX, explores how aligning the science of thinking, learning, and doing can reduce deviations, enhance performance, and accelerate trial success.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391137383112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/data-overload-problem-facing-wearable-integration-clinical-care</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/af999c99d7940c6a7941fd531185ce28569013b7-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Data Overload Problem Facing Wearable Integration in Clinical Care ]]></video:title><video:description><![CDATA[In this video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, examines the operational challenges of incorporating wearable data into clinical workflows, including information overload and false alarm fatigue, and what those obstacles mean for patient safety.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391086426112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/remote-monitoring-shifting-care-reactive-proactive</loc><video:video><video:publication_date>2026-03-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/05e9ea2e7a980ab6bcb8f5909939cccbea236b4c-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Remote Monitoring Is Shifting Care From Reactive to Proactive ]]></video:title><video:description><![CDATA[In this video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, explains how continuous remote monitoring enables earlier detection of patient deterioration and allows care teams to intervene before conditions escalate to hospitalization.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391086633112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/wearable-data-clinical-visits</loc><video:video><video:publication_date>2026-03-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/b6f078191f7caa2ee1f852a4c3e5f0cdbadc86a6-1280x720.png</video:thumbnail_loc><video:title><![CDATA[What Wearable Data Reveals That Clinical Visits Cannot ]]></video:title><video:description><![CDATA[In this video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, discusses how wearable devices are giving clinicians a unique window into patient health outside the clinic and why that real-world visibility is becoming essential to modern care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6391085473112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/method-revolutionize-trial-outcomes-analyzed</loc><video:video><video:publication_date>2026-03-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/c0a4fb1e8f3bb850a66ccabe3f493f9db5eef4f1-1280x720.png</video:thumbnail_loc><video:title><![CDATA[A Method That Could Revolutionize How Trial Outcomes Are Analyzed ]]></video:title><video:description><![CDATA[In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, makes the case for generalized pairwise comparisons and the win ratio as transformative approaches to trial analysis that incorporate multiple outcomes simultaneously and better reflect what matters most to patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390644192112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/early-planning-biostatistics-trial-success</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/44fdea03530aae0145a1fced44dc9fb031a51739-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Early Planning and Biostatistics Are Central to Trial Success]]></video:title><video:description><![CDATA[In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, explains how early-stage planning, the estimand framework, and anticipating trial conduct problems can protect data integrity and make results more convincing and actionable.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390644755112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/a-physician-led-clinical-trial-network</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/4cabdd546cb389ebeb66799a20dc17c7e337f893-1566x954.png</video:thumbnail_loc><video:title><![CDATA[A Physician-led Clinical Trial Network]]></video:title><video:description><![CDATA[Corey Collins, CEO of Tekton Research, and Taryn Collett, COO of Tekton Research, discuss how Tekton's approach and collaboration with others is speeding up disease research. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390791661112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/sponsor-expectations-reshaping-data-strategy-trial-design</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/dfce8d77932db9ec96f69700ed302bb57916e168-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Sponsor Expectations Are Reshaping Data Strategy and Trial Design ]]></video:title><video:description><![CDATA[In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, reflects on the gap between sponsor expectations and statistical reality, drawing on lessons from the COVID era to argue for more pragmatic, cost-efficient trial execution and greater patient access to clinical research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390645255112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/operational-gaps-undermine-trial-data-quality</loc><video:video><video:publication_date>2026-03-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/a2d98412a158eb4a1ba32ec4bcb1eda3c45a6c54-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Operational Gaps That Undermine Trial Data Quality ]]></video:title><video:description><![CDATA[In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, examines the most common threats to trial data reliability, including opaque methodologies, synthetic controls, and the limits of AI-driven analysis, while making the case for explainable, transparent trial design.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390645825112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinical-trial-data-trust</loc><video:video><video:publication_date>2026-03-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/5520d0ade0401578fb1ae0a6cc6f16a254ffad80-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Clinical Trial Data Is Getting Harder to Trust ]]></video:title><video:description><![CDATA[In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, discusses how increasing trial complexity is making data interpretation less straightforward and why transparency and reproducibility are now essential.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390644370112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/bayesian-design-reshaping-clinical-development</loc><video:video><video:publication_date>2026-03-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9e76a81e5b8e0a5bde413dad691e56b8d520f807-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Bayesian Design Is Reshaping Clinical Development]]></video:title><video:description><![CDATA[In this video interview, David Morton, PhD, director of biostatistics at Certara, reflects on the growing role of Bayesian approaches in modern drug development, emphasizing their potential to improve decision-making, efficiency, and overall trial success.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390321532112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/building-smarter-trials-bayesian-statistics</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/a5ced45e7261d7b90e5af0d0c030e2005a8cd959-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Building Smarter Trials With Bayesian Statistics]]></video:title><video:description><![CDATA[In this video interview, David Morton, PhD, director of biostatistics at Certara, explores the practical challenges of implementing Bayesian designs, including the need for simulation, cross-functional alignment, and clear communication with regulators.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390322018112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/rethinking-trial-design-bayesian-approaches</loc><video:video><video:publication_date>2026-03-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/75428824bf71d30eb737c7d7069ff172a4e02a6e-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Rethinking Trial Design With Bayesian Approaches]]></video:title><video:description><![CDATA[In this video interview, David Morton, PhD, director of biostatistics at Certara, outlines how increasing FDA support is helping drive adoption of Bayesian methods, particularly in rare disease and small population studies where efficiency is critical.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390321533112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/fda-support-drives-shift-toward-bayesian-trial-design</loc><video:video><video:publication_date>2026-03-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/7f89b987d33b6b22e5278c984e148665d91543a8-1280x720.png</video:thumbnail_loc><video:title><![CDATA[FDA Support Drives Shift Toward Bayesian Trial Design]]></video:title><video:description><![CDATA[In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is encouraging sponsors to move beyond traditional methods, leveraging Bayesian frameworks to improve efficiency, particularly in rare disease and small population studies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390319689112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/advancing-bayesian-methods-clinical-trials</loc><video:video><video:publication_date>2026-03-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/6b7ae5fed02dbe1f34b0391baab5949603c001f8-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Advancing Bayesian Methods in Clinical Trials]]></video:title><video:description><![CDATA[In this video interview, David Morton, PhD, director of biostatistics at Certara, discusses how growing FDA support is accelerating the adoption of Bayesian approaches, enabling more flexible, data-driven trial designs through external data borrowing, adaptive decision-making, and simulation-based planning.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6390321140112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinical-ops-leaders-prioritize-data-flow-scalable-workflows</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/0691e9a84b891bfdb4cbe30488ed01c0928abb81-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Clinical Ops Leaders Must Prioritize Data Flow and Scalable Workflows]]></video:title><video:description><![CDATA[Jonathan Andrus, co-CEO of CRIO, discusses how governance across the data lifecycle, site-focused technology adoption, and scalable AI-enabled workflows will define operational readiness in 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389763606112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/collaboration-protocol-design</loc><video:video><video:publication_date>2026-02-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/138d386a5079c4770923925a07eebe50c1428e9c-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Collaboration Must Start at Protocol Design]]></video:title><video:description><![CDATA[Jonathan Andrus, co-CEO of CRIO, highlights the need for earlier cross-functional collaboration and greater site involvement to ensure data quality, workflow alignment, and operational success.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389763230112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/the-patient-site-relationship-why-it-s-crucial-and-how-to-support-it</loc><video:video><video:publication_date>2026-02-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/85cc267f3492864c05e351120569247df11a59bf-854x480.png</video:thumbnail_loc><video:title><![CDATA[The Patient-Site Relationship: Why It’s Crucial and How to Support It]]></video:title><video:description><![CDATA[Steve Rosenberg, CEO of uMotif, explores the core challenges of clinical trial recruitment and retention, and discusses how digital tools empower sites and patients to build more effective, trust-based relationships. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389887841112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/fragmentation-remains-biggest-data-risk</loc><video:video><video:publication_date>2026-02-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/2b5e733d05456adfdead28c4d053448c4b14ad16-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Fragmentation Remains the Biggest Data Risk]]></video:title><video:description><![CDATA[Jonathan Andrus, co-CEO of CRIO, outlines how disconnected systems and inconsistent data collection across sites create risk, while centralized eSource approaches present a major opportunity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389762628112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/protocol-driven-esource-advances-study-efficiency</loc><video:video><video:publication_date>2026-02-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/fc4f22a9ca8c2625254824380b6d632c404fd57f-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Protocol-Driven eSource Advances Study Efficiency]]></video:title><video:description><![CDATA[Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389763900112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/site-based-technologies-data-quality-compliance</loc><video:video><video:publication_date>2026-02-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/de79d40b5823e6a0c9448944d980037404185b4f-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Site-Based Technologies Drive Data Quality and Compliance]]></video:title><video:description><![CDATA[Jonathan Andrus, co-CEO of CRIO, discusses how increased reliance on site-based technologies and eSource is strengthening data quality, compliance, and trust at the point of patient encounter.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389761754112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/sponsors-act-now-stay-competitive</loc><video:video><video:publication_date>2026-02-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/32b7856225e2353eb34ba3a0daed04bc79d258bc-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Sponsors Must Act Now to Stay Competitive]]></video:title><video:description><![CDATA[Angela Zubel, chief development officer, Debiopharm, emphasizes that organizations willing to standardize data and adopt practical AI tools are already gaining efficiency, cost savings, and stronger real-time oversight across development programs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389188422112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/promise-imits-predictive-analytics-oncology</loc><video:video><video:publication_date>2026-02-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/2ecd29789bf5f12547b53cf3367f7bf6475de269-1280x720.png</video:thumbnail_loc><video:title><![CDATA[The Promise and Limits of Predictive Analytics in Oncology]]></video:title><video:description><![CDATA[Angela Zubel, chief development officer, Debiopharm, outlines how predictive models are improving compound selection from early clinical phases, while noting the ongoing challenges of forecasting success from preclinical development to patient outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389188844112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/real-time-monitoring-smarter-site-allocation-efficiency-drivers</loc><video:video><video:publication_date>2026-02-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/6c8c89a7d635b6185be6a30e51b3313843db1160-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Real-Time Monitoring and Smarter Site Allocation as Efficiency Drivers]]></video:title><video:description><![CDATA[Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit inefficiencies caused by non-performing sites.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389189316112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/2026-implementation-year-ai-drug-development</loc><video:video><video:publication_date>2026-02-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/09902ef1986b2d9de54c9b00fcc3e60d22b094c4-1280x720.png</video:thumbnail_loc><video:title><![CDATA[2026 as an Implementation Year for AI in Drug Development]]></video:title><video:description><![CDATA[Angela Zubel, chief development officer, Debiopharm, discusses why 2026 marks a shift from AI pilots to broader operational implementation across clinical trials and drug development programs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389189315112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/from-journey-to-action-using-longitudinal-patient-level-insights-to-de-risk-and-accelerate-clinical-trials</loc><video:video><video:publication_date>2026-02-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/37b5eae412829f7ff6db17c6d72c3ece0122db75-1280x720.png</video:thumbnail_loc><video:title><![CDATA[From Journey to Action: Using Longitudinal Patient-Level Insights to De-Risk and Accelerate Clinical Trials]]></video:title><video:description><![CDATA[In this interview, Skye Hodson, PhD, of Citeline, explains how longitudinal, patient-level insights across the full care journey are helping sponsors overcome enrollment delays, investigator scarcity, and protocol complexity—transforming strategy into execution-ready deliverables that optimize feasibility, site selection, and measurable recruitment outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389357408112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-patient-centered-strategy-recruitment-retention</loc><video:video><video:publication_date>2026-02-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9dc3fafdbb8079af89613cc20df9b2407624ef19-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Patient-Centered Strategy as a Driver of Recruitment and Retention]]></video:title><video:description><![CDATA[Miriam Dervan, founder & CEO of mdgroup, discusses how patient-centered strategies rooted in empathy and advocacy engagement can strengthen recruitment, retention, and overall trial execution.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389131679112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-advancing-digital-endpoints-regulatory-alignment</loc><video:video><video:publication_date>2026-02-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/4c1518b4100e9c598054082e07d195223038035b-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Advancing Digital Endpoints Through Performance and Regulatory Alignment]]></video:title><video:description><![CDATA[Jeremy Wyatt, CEO, Ametris, explains how digital endpoints improve trial sensitivity, patient centricity, and efficiency through continuous real-world data, and why early regulatory collaboration is essential to reducing adoption risk and establishing consistent validation standards across programs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389129666112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-aligning-ai-oversight-esource-ehr-foundations</loc><video:video><video:publication_date>2026-02-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9dfbc156bb388ec53694035375e2c606c59b08d6-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Aligning AI Oversight With Strong eSource and EHR Foundations]]></video:title><video:description><![CDATA[Mike Wenger, chief innovation officer at CRIO, explains how AI can responsibly support data quality and monitoring with proper oversight, and why advancing eSource and EHR systems remains critical to strengthening data integrity and remote trial operations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389086059112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-payment-practices-operational-burden-site-behavior</loc><video:video><video:publication_date>2026-02-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/3bf10f4ac09be5d3fd9be719338429810c2e8162-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: How Payment Practices and Operational Burden Are Changing Site Behavior]]></video:title><video:description><![CDATA[Holly Leslie, vice president of services at Ledger Run, discusses how persistent payment friction, increasing administrative burden from AI-generated queries, and lack of sponsor accountability are pushing sites to become more selective—favoring sponsors that pay transparently, reduce operational strain, and treat site experience with the same rigor as patient recruitment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389046520112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-esg-core-measure-clinical-research-quality</loc><video:video><video:publication_date>2026-02-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/c916881c6bbd27725c6a6445f090b08fc472db5b-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Making ESG a Core Measure of Clinical Research Quality]]></video:title><video:description><![CDATA[Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses why suppliers must shift from ESG activity to decision-grade evidence, and how embedding sustainability into clinical research quality could reshape sponsor expectations, oversight, and supplier selection in the years ahead.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6389000302112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-sponsors-prioritizing-ai-adoption-clinical-trials</loc><video:video><video:publication_date>2026-02-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/1332d482945e55f49e50efc401a9a542417d38aa-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: How Sponsors Are Prioritizing AI Adoption Across Clinical Trials]]></video:title><video:description><![CDATA[Raja Shankar, VP of machine learning at IQVIA, discusses which AI capabilities sponsors are most likely to adopt first to streamline trial workflows and reduce operational burden, while also highlighting emerging applications that could shape the next phase of clinical trial design.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388996305112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-reducing-patient-burden-foundation-wearable-success-oncology</loc><video:video><video:publication_date>2026-02-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/9bb9af3d1b0498221e3d139e7f7e3f09e399d55d-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Reducing Patient Burden Is the Foundation of Wearable Success in Oncology]]></video:title><video:description><![CDATA[Jeremy Wyatt, CEO, Ametris, discusses how operational best practices for integrating wearables into oncology trials center on minimizing patient burden through thoughtful workflow design, careful device selection, and early planning to ensure digital measures fit the realities of complex patient populations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388819646112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/evolving-fda-risk-tolerance-reshapes-global-trial-alignment</loc><video:video><video:publication_date>2026-02-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/2a58a4be1f279d7f7d05d04e152ffb18583050a2-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Evolving FDA Risk Tolerance Reshapes Global Trial Alignment]]></video:title><video:description><![CDATA[Charlie Paterson, partner at PA Consulting, explains how mixed signals on FDA risk tolerance are accelerating the globalization of clinical trial programs and reshaping how sponsors align development activities worldwide.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388448378112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-elevating-patient-experience-clinical-operations</loc><video:video><video:publication_date>2026-02-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/7631574440955b45c22684d2b99de811272dc82c-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations]]></video:title><video:description><![CDATA[Miriam Dervan, founder & CEO of mdgroup, explains how treating patient experience as a strategic investment—rather than a secondary consideration—changes how sponsors, sites, and operational teams design and deliver clinical trials.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388780564112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-understanding-esource</loc><video:video><video:publication_date>2026-02-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/5ae1a6e068a54cc2cb4a73f5a278934fa8a52c69-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Understanding the Different Flavors of eSource]]></video:title><video:description><![CDATA[Mike Wenger, chief innovation officer at CRIO, discusses how different site types—from academic medical centers to independent research sites—require distinct eSource approaches, and why aligning technology with site workflows is critical to study execution.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388778329112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-site-selectivity-sponsor-relationships</loc><video:video><video:publication_date>2026-02-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/433876e0fbcec98564af3fec1f3cf9116d20ea9a-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Why Site Selectivity Is Beginning to Reshape Sponsor Relationships]]></video:title><video:description><![CDATA[Holly Leslie, vice president of services at Ledger Run, explains why site selectivity is not yet universal, but increasingly driven by larger, more sophisticated sites that are demanding stronger remuneration policies and greater leverage in sponsor relationships.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388725504112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-esg-reporting-vendor-readiness-test-clinical-operations</loc><video:video><video:publication_date>2026-02-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/39269c3b014dac32c04dc432c47a806c0f079b18-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations]]></video:title><video:description><![CDATA[Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses how ESG is evolving from a reporting exercise into an auditable measure of operational readiness, and what that shift means for sponsor expectations, vendor qualification, and supplier governance discipline.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388722641112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-ai-immediate-impact-rd</loc><video:video><video:publication_date>2026-02-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/709dbb5440c76312ffe905da39f74f01a4100e7e-1280x720.png</video:thumbnail_loc><video:title><![CDATA[SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D]]></video:title><video:description><![CDATA[Raja Shankar, VP of machine learning at IQVIA, explains how AI-driven trial simulation and automation are beginning to influence decision-making across every phase of clinical development.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388550257112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/regulatory-uncertainty-emerges-drug-development-lifecycle</loc><video:video><video:publication_date>2026-02-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/f212d205e89945cf648656c751864fe3e9ab2d73-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Regulatory Uncertainty Emerges Across the Drug Development Lifecycle]]></video:title><video:description><![CDATA[Charlie Paterson, partner at PA Consulting, describes how FDA capacity constraints are creating uncertainty from initial submissions through late-stage approval, elongating timelines and influencing global development strategies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388448173112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/clinical-operations-teams-adjust-evidence-engagement-gaps</loc><video:video><video:publication_date>2026-02-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/a709c0a49a8251052d68d580753a649ee20c70a2-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Clinical Operations Teams Adjust to Evidence and Engagement Gaps]]></video:title><video:description><![CDATA[Charlie Paterson, partner at PA Consulting, outlines how limited FDA guidance on innovative designs, decentralized models, and digital endpoints is forcing clinical operations teams to recalibrate expectations and minimize regulatory risk.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388447877112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/slower-fda-guidance-pushes-sponsors-toward-legacy-approaches</loc><video:video><video:publication_date>2026-01-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/18b6a1671095f37eb9a87fa007e6794f06aa38c6-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches]]></video:title><video:description><![CDATA[Charlie Paterson, partner at PA Consulting, discusses how fewer new guidance updates are pushing sponsors to rely on historical precedents and non-US standards when making trial design and operational decisions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388445937112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/fda-staffing-constraints-extend-planning-review-timelines</loc><video:video><video:publication_date>2026-01-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/3fd9286a010c0c0a7cf38b6d5dc10e773ecfbe1d-1280x720.png</video:thumbnail_loc><video:title><![CDATA[FDA Staffing Constraints Extend Planning and Review Timelines]]></video:title><video:description><![CDATA[Charlie Paterson, partner at PA Consulting, explains how reduced FDA capacity and staff turnover have led to longer regulatory timelines, increased preparation for agency interactions, and delayed feedback during early trial planning.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388446333112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/real-world-evidence-change-trials-replacing</loc><video:video><video:publication_date>2026-01-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/1d8a0c349356dfe3e8e687675be6bcd8b849c248-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Real-World Evidence Will Change Trials Without Replacing Them]]></video:title><video:description><![CDATA[See how real-world evidence is enabling smaller, smarter, and more efficient trial designs through hybrid models, external comparators, and continuous patient monitoring—while preserving the role of traditional clinical trials.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388095149112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/operational-governance-barriers-regulatory-rwe</loc><video:video><video:publication_date>2026-01-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/6d48eb86abd6b7bdc9e41e5e20e033f7c311cfcb-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Operational and Governance Barriers to Regulatory-Grade RWE]]></video:title><video:description><![CDATA[Assess the data quality, linkage, transparency, and auditability challenges that sponsors must overcome to make de-identified real-world evidence fit for regulatory submissions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388096299112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/real-world-evidence-clinical-research-spectrum</loc><video:video><video:publication_date>2026-01-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/ed30a62362db9a4b27c76cf15e22caeee9bf4655-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Where Real-World Evidence Fits Along the Clinical Research Spectrum]]></video:title><video:description><![CDATA[Understand where real-world evidence most effectively complements or substitutes traditional trial data, from post-market surveillance and label expansion to challenging areas such as rare disease research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388095150112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/using-de-identified-data-rethink-trial-design-site-strategy</loc><video:video><video:publication_date>2026-01-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/0f91314671a33e32232b0e4a4871f5ea3bbcae90-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Using De-Identified Data to Rethink Trial Design and Site Strategy]]></video:title><video:description><![CDATA[Explore how large-scale, de-identified real-world datasets enable more representative trial design, improve site selection, and support patient identification beyond the limits of traditional clinical study populations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388094250112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/fda-rwe-guidance-redefines-data-use-clinical-operations</loc><video:video><video:publication_date>2026-01-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/7060daab0a21cea50f22a1bd555ee2de450d33da-1280x720.png</video:thumbnail_loc><video:title><![CDATA[FDA RWE Guidance Redefines Data Use in Clinical Operations]]></video:title><video:description><![CDATA[Examine how the FDA’s acceptance of de-identified real-world evidence shifts clinical operations workflows and why understanding the difference between pseudonymized and anonymized data is now critical for privacy, compliance, and evidence generation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6388096687112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/centering-site-experience-accelerate-study-activation</loc><video:video><video:publication_date>2026-01-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/d9ed5c95eb435a925bd4927730efa94d89a3ab60-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Centering Site Experience to Accelerate Study Activation]]></video:title><video:description><![CDATA[Consider how sponsor and CRO practices that prioritize site needs, clarity, and partnership can strengthen trust, sustain momentum, and speed activation without sacrificing the human experience.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6387773671112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/startup-timelines-worsening-reverse-trend</loc><video:video><video:publication_date>2026-01-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/97d2a69abdee9db1873fb4b2a234ef66a3365a14-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Why Startup Timelines Are Worsening—and How to Reverse the Trend]]></video:title><video:description><![CDATA[Analyze the operational pressures driving longer activation timelines, from protocol complexity to site competition, and learn how earlier, more flexible site engagement can restore momentum.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6387775708112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/applying-ai-reduce-administrative-burden-human-touch</loc><video:video><video:publication_date>2026-01-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/926a22ad47b5ac24bfa03fa9c87fcd17728260d3-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Applying AI to Reduce Administrative Burden Without Losing the Human Touch]]></video:title><video:description><![CDATA[Examine how practical AI applications can streamline contracts and startup workflows while preserving the central role of investigators, site staff, and patient relationships in clinical research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6387774937112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/closing-communication-gaps-during-study-startup</loc><video:video><video:publication_date>2026-01-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/c0068d8eff0dcb92c4d4c4d8826c4e939b20d416-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Closing Communication Gaps During Study Startup]]></video:title><video:description><![CDATA[Unpack why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how bidirectional, site-informed engagement models can improve collaboration and momentum.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6387773966112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/rethinking-site-activation-cut-startup-timelines</loc><video:video><video:publication_date>2026-01-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/f92a76ce6991d19032a0ae2b6a199370a9b8a8f0-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Rethinking Site Activation to Cut Startup Timelines]]></video:title><video:description><![CDATA[Explore how contract standardization, proactive budget alignment, and AI-enabled negotiation tools can reduce site activation delays and turn agreements into strategic accelerators rather than administrative bottlenecks.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6387774232112</video:player_loc></video:video></url><url>
        <loc>https://www.appliedclinicaltrialsonline.com/view/ai-pilot-mode-clinical-development</loc><video:video><video:publication_date>2026-01-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/act/39e45b1c72f130f1d1b494ab00a9a9bc5b5b8000-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Breaking Out of AI Pilot Mode in Clinical Development]]></video:title><video:description><![CDATA[See what will distinguish sponsors that scale AI into core operations from those stuck in experimentation, and why redesigning underlying processes—not just optimizing workflows—is critical to realizing long-term value.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/1265527929001/default_default/index.html?videoId=6387373314112</video:player_loc></video:video></url></urlset>